Asco 2021 – the exon 20 army lines up behind Rybrevant
A new lung cancer niche is a major focus of Asco, with China's Dizal perhaps boasting the most intriguing dataset.
Asco 2021 – Alkermes’s disappointment hones melanoma niche focus
Alkermes plays up responses in mucosal melanoma, but those hoping for an IL-2 renaissance might be disappointed.
Asco 2021 – Merus’s slight improvement might not win over investors
The group still has its eye on accelerated approval, though genetic testing casts a long shadow.
Asco 2021 justifies Novartis’s radioligand Vision
177Lu-PSMA-617 shows impressive survival results in the Vision study, but early use will be key to fulfilling its potential.
Asco 2021 – Bristol makes more progress in stomach cancer
But the space, a battle between Opdivo and Keytruda, is becoming extremely complex, and Bristol’s win is not unequivocal.
Asco 2021 – financial toxicity in the spotlight
The long overdue advent of US cut-price oncology drugs is a major theme at this year’s Asco, and Junshi’s toripalimab leads the way.
Asco 2021 – full Olympia results sweep away Parp doubts
Lynparza could become the first Parp inhibitor approved for adjuvant use, an Asco late-breaker reveals.
Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Asco 2021 – Abstract lift drives first stock moves
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
